RTOG 0131: Phase II trial of pre-irradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligodendrogliomas: Relationship between 1p/19q status and progression-free survival Article

Vogelbaum, MA, Berkey, B, Peereboom, D et al. (2006). RTOG 0131: Phase II trial of pre-irradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligodendrogliomas: Relationship between 1p/19q status and progression-free survival . JOURNAL OF CLINICAL ONCOLOGY, 24(18_suppl), 1517-1517. 10.1200/jco.2006.24.18_suppl.1517

cited authors

  • Vogelbaum, MA; Berkey, B; Peereboom, D; Giannini, C; Jenkins, R; Suh, J; Brown, P; Blumenthal, D; Biggs, C; Mehta, M

authors

publication date

  • June 20, 2006

published in

keywords

  • 32 Biomedical and Clinical Sciences
  • 3202 Clinical Sciences
  • 3211 Oncology and Carcinogenesis
  • 6 Evaluation of treatments and therapeutic interventions
  • 6.1 Pharmaceuticals
  • Brain Cancer
  • Brain Disorders
  • Cancer
  • Clinical Research
  • Clinical Trials and Supportive Activities
  • Rare Diseases

Digital Object Identifier (DOI)

publisher

  • American Society of Clinical Oncology (ASCO)

start page

  • 1517

end page

  • 1517

volume

  • 24

issue

  • 18_suppl